Developer docs
API playgroundTry for free, no card

Search company profiles

HempMeds

Full company profile

uuid000vgx7

Namestring
HempMeds
Websiteurl
hempmedsbr.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

HempMeds is a privately held, for-profit company headquartered in São Paulo, Brazil, founded in 2014, that specializes in the distribution of cannabis-based products for medicinal purposes, with an associated patient support offering. The firm operates at a small scale, with 11–50 employees per available firmographic data, and presents itself to the Brazilian medicinal cannabis market via the domain hempmedsbr.com. Its functional role sits at the intersection of regulated product distribution and patient-facing support services in a market that is tightly controlled by Brazil's health regulator, ANVISA.

The business model is anchored in regulated distribution of cannabis-derived therapeutics combined with patient support, implying revenue is generated through product sales (and potentially associated support/consultation services) to patients, prescribers, or pharmacy channels. No pricing model, contract structure, GTM motion, or revenue mechanics are disclosed in the available source data, and no management team, ownership structure, funding history, or financial disclosures are available. The primary website content consists only of a loading/verification page, which limits deeper verification of product catalog, certifications, partnerships, and operational footprint.

The company's strategic position rests largely on first-mover timing (2014 founding) within Brazil's evolving medicinal cannabis regulatory framework, and on the association with the broader HempMeds brand known internationally in cannabis distribution. However, evidence of current commercial momentum — including revenue scale, headcount trajectory, recent product launches, partnerships, or capital raises — is absent from the dataset, and several core firmographic fields (legal name, founding date precision, parent/subsidiary structure, customer segments) remain blank or unverified.

Short descriptiontext

HempMeds is a São Paulo-based, privately held company founded in 2014 that distributes cannabis-based medicinal products in Brazil and provides patient support services. It operates with a small team of 11–50 employees within Brazil's regulated medicinal cannabis market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSão Paulo, Brazil
HQ citystring
São Paulo
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
cannabis distribution, medicinal hemp products, CBD wellness products, cannabis-based supplements, hemp-derived therapeutics
Industry3 codes
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAA
CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medicinal Cannabis Products
No data
Cost components4 values
Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HempMeds specializes in the distribution of cannabis-based products for medicinal purposes, accompanied by patient support services. The company is headquartered in São Paulo, Brazil, and was founded in 2014, operating in the medicinal cannabis segment with a focus on supporting patients seeking cannabis-derived therapeutic options.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CBD-focused brand selling tinctures, capsules, and topicals to health-and-wellness consumers; comparable product mix and medicinal-adjacent positioning.

TypeDirect peer
Description

US-listed holding company; HempMeds is its Brazilian distribution arm, and the parent operates the same hemp-derived wellness product line under the HempMeds and Real Scientific Hemp Oil brands.

3Tilray Brands
TypeBroad incumbent
Description

Global cannabis company with established medical cannabis operations in Brazil through Tilray Latin America; directly comparable medical distribution footprint in the same geography.

TypeBroad incumbent
Description

Large Canadian licensed producer with global medical cannabis distribution including LATAM; competes for the same Brazilian prescription and specialty channel as HempMeds.

TypeEmerging player
Description

Hemp-derived CBD/cannabinoid wellness company selling tinctures, capsules, and topicals internationally; comparable therapeutic product portfolio to HempMeds.

TypeDirect peer
Description

Vertically integrated hemp-derived CBD wellness brand with a medicinal/health positioning similar to HempMeds' product line, including tinctures and topicals.

TypeEmerging player
Description

Hemp-derived CBD brand with a strong wellness/therapeutic positioning, overlapping in target customer profile with HempMeds' medicinal users.

TypeDirect peer
Description

CBD wellness company founded by pharmacists, distributing tinctures, topicals, and edibles through retail and DTC channels; comparable regulated-pharmacy-adjacent positioning.

TypeDirect peer
Description

Vertically integrated CBD brand emphasizing accessibility and therapeutic use cases; comparable medicinal-wellness positioning and SKU mix.

TypeDirect peer
Description

Medical cannabis company focused on Latin America, with a strong Brazil presence; comparable target customers (prescribers, patients) and distribution-led model.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HempMeds

Medicinal Cannabis Productshempmedsbr.com

HempMeds is a São Paulo-based, privately held company founded in 2014 that distributes cannabis-based medicinal products in Brazil and provides patient support services. It operates with a small team of 11–50 employees within Brazil's regulated medicinal cannabis market.

What HempMeds does

HempMeds is a privately held, for-profit company headquartered in São Paulo, Brazil, founded in 2014, that specializes in the distribution of cannabis-based products for medicinal purposes, with an associated patient support offering. The firm operates at a small scale, with 11–50 employees per available firmographic data, and presents itself to the Brazilian medicinal cannabis market via the domain hempmedsbr.com. Its functional role sits at the intersection of regulated product distribution and patient-facing support services in a market that is tightly controlled by Brazil's health regulator, ANVISA.

The business model is anchored in regulated distribution of cannabis-derived therapeutics combined with patient support, implying revenue is generated through product sales (and potentially associated support/consultation services) to patients, prescribers, or pharmacy channels. No pricing model, contract structure, GTM motion, or revenue mechanics are disclosed in the available source data, and no management team, ownership structure, funding history, or financial disclosures are available. The primary website content consists only of a loading/verification page, which limits deeper verification of product catalog, certifications, partnerships, and operational footprint.

The company's strategic position rests largely on first-mover timing (2014 founding) within Brazil's evolving medicinal cannabis regulatory framework, and on the association with the broader HempMeds brand known internationally in cannabis distribution. However, evidence of current commercial momentum — including revenue scale, headcount trajectory, recent product launches, partnerships, or capital raises — is absent from the dataset, and several core firmographic fields (legal name, founding date precision, parent/subsidiary structure, customer segments) remain blank or unverified.

HempMeds firmographics

Firmographics
Name
HempMeds
Website
https://hempmedsbr.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
HempMeds is a São Paulo-based, privately held company founded in 2014 that distributes cannabis-based medicinal products in Brazil and provides patient support services. It operates with a small team of 11–50 employees within Brazil's regulated medicinal cannabis market.
Ownership category
akta.pro rank

HempMeds industry classification

Industry
Product category
Medicinal Cannabis Products
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAA
CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution

Keywords

  • Cannabis distribution
  • Medicinal hemp products
  • CBD wellness products
  • Cannabis-based supplements
  • Hemp-derived therapeutics

Where HempMeds is headquartered

Location

Headquarters

HQ city
São Paulo
HQ country
Brazil
HQ region
Latin America

Markets served

HempMeds business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales

HempMeds product offering

Product offering

Core offering

HempMeds specializes in the distribution of cannabis-based products for medicinal purposes, accompanied by patient support services. The company is headquartered in São Paulo, Brazil, and was founded in 2014, operating in the medicinal cannabis segment with a focus on supporting patients seeking cannabis-derived therapeutic options.

Differentiator

Problem solved

Functional benefit

Companies that use HempMeds

Customer profile

Ideal customer profiles1 record

HempMeds technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

HempMeds partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

HempMeds competitors and assessment

Company assessment

Direct peers

  • CBDistillery: CBD-focused brand selling tinctures, capsules, and topicals to health-and-wellness consumers; comparable product mix and medicinal-adjacent positioning.
  • Medical Marijuana Inc. US-listed holding company; HempMeds is its Brazilian distribution arm, and the parent operates the same hemp-derived wellness product line under the HempMeds and Real Scientific Hemp Oil brands.
  • Charlotte's Web: Vertically integrated hemp-derived CBD wellness brand with a medicinal/health positioning similar to HempMeds' product line, including tinctures and topicals.
  • Green Roads: CBD wellness company founded by pharmacists, distributing tinctures, topicals, and edibles through retail and DTC channels; comparable regulated-pharmacy-adjacent positioning.
  • Lazarus Naturals: Vertically integrated CBD brand emphasizing accessibility and therapeutic use cases; comparable medicinal-wellness positioning and SKU mix.
  • Khiron Life Sciences: Medical cannabis company focused on Latin America, with a strong Brazil presence; comparable target customers (prescribers, patients) and distribution-led model.

Broad incumbents

  • Tilray Brands: Global cannabis company with established medical cannabis operations in Brazil through Tilray Latin America; directly comparable medical distribution footprint in the same geography.
  • Canopy Growth Corporation: Large Canadian licensed producer with global medical cannabis distribution including LATAM; competes for the same Brazilian prescription and specialty channel as HempMeds.

Emerging players

  • Endoca: Hemp-derived CBD/cannabinoid wellness company selling tinctures, capsules, and topicals internationally; comparable therapeutic product portfolio to HempMeds.
  • Elixinol Wellness: Hemp-derived CBD brand with a strong wellness/therapeutic positioning, overlapping in target customer profile with HempMeds' medicinal users.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights3 records

Customer concentration

HempMeds financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HempMeds leadership team

Management profile

Number of profiles

HempMeds funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HempMeds M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HempMeds

What does HempMeds do?

HempMeds specializes in the distribution of cannabis-based products for medicinal purposes, accompanied by patient support services. The company is headquartered in São Paulo, Brazil, and was founded in 2014, operating in the medicinal cannabis segment with a focus on supporting patients seeking cannabis-derived therapeutic options.

Is HempMeds a public or private company?

HempMeds is a private company. It is classified as unknown and is currently operating.

When was HempMeds founded?

HempMeds was founded in 2014. It employs 11 to 50 people.

Where is HempMeds based?

HempMeds is headquartered in São Paulo, Brazil, in the Latin America region.

Who are HempMeds's main competitors?

Direct peers on record are CBDistillery, Medical Marijuana Inc., Charlotte's Web, Green Roads, Lazarus Naturals and Khiron Life Sciences. Broad incumbents are Tilray Brands and Canopy Growth Corporation. Emerging players are Endoca and Elixinol Wellness.

Does HempMeds have an API?

No public API is recorded for HempMeds.

What industry is HempMeds in?

HempMeds's product category is Medicinal Cannabis Products. Its primary akta.pro industry code is CRANAHAC, CBD/Hemp Wellness & Supplements Retail, with a secondary code of CRANAHAA, CBD/Hemp Specialty Stores (Tinctures, Oils, Edibles). Its NAICS code is 42421 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMedical Marijuana, Inc. Subsidiary HempMeds Brasil Celebrates Feature in ForbesHempMeds Brasil, a subsidiary of Medical Marijuana, Inc., was featured in Forbes for its growth in Brazil. The company has grown 50% year over year since 2014 and imported over 140,000 cannabis-derived products. In Q1 2022, it grew 75.8% faster than the overall CBD market.GlobeNewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Celebrates Exponential Growth; Receives Validation From Medical CommunityHempMeds Brasil, a subsidiary of Medical Marijuana, Inc., reported growth 75.8% faster than Brazil's CBD market in Q1 2022. The company was featured in a medical magazine for its course on Cannabinoid Medicine. It expects continued growth as competitors exit the market.GlobeNewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces August 2020 as the Best Revenue Month in Company HistoryHempMeds Brasil, a subsidiary of Medical Marijuana, Inc., reported its best revenue month in August 2020. Since 2015, the company has sold over 80,000 CBD units to Brazilian citizens, and it is working on additional approvals for other indications.PR NewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Hosts Largest Digital Event in Company HistoryMedical Marijuana, Inc.'s subsidiary HempMeds® Brasil hosted its largest digital event in company history, an Instagram Live webinar featuring MasterChef Brazil judge Henrique Fogaça that attracted over 13,000 attendees. Fogaça shared how his epileptic daughter uses HempMeds' Real Scientific Hemp Oil CBD product, while the company highlighted Brazil's projected $448 million CBD market by 2023. HempMeds Brasil, which was the first company to receive ANVISA approval to import CBD into Brazil, plans to continue hosting additional digital events throughout May.PR NewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Applauds ANVISA's New Regulations of Medical Cannabis Products in BrazilANVISA (Brazil's National Agency for Health Supervision) unanimously approved regulations allowing medical marijuana products to be sold at pharmacies and drugstores nationwide, with the law taking effect 90 days after publication in the Federal Official Gazette. Medical Marijuana, Inc. subsidiary HempMeds® Brasil, which was the first company to receive ANVISA approval to import CBD into Brazil, applauded the decision, noting it will provide approximately four million Brazilian patients easier access to CBD products. The company's sales bookings through Q3 2019 already surpassed total 2018 bookings and are on pace to grow more than 50% year over year.PR NewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Vice President Hosts Panel at Lide Futuro Debate in São PauloMedical Marijuana, Inc. subsidiary HempMeds® Brasil Vice President Caroline Heinz hosted a panel at the Lide Futuro Debate in São Paulo, Brazil on October 18, 2019, titled "Strategic Movements as a New Regulatory Framework." The panel discussed upcoming Brazilian cannabis regulations including cultivation for medical and research purposes and changes to cannabis product registration as controlled medicines. A New Frontier Data survey cited in the article projects Brazil's cannabis market could reach approximately $4.4 billion by 2022, equivalent to 6.3 percent of total Brazilian pharmaceutical industry revenue.PR NewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Signs Agreement with Online Marketplace Dr. CannabisMedical Marijuana, Inc. announced that its subsidiary HempMeds® Brasil has signed an agreement to become the exclusive Brazilian reseller of the company's CBD products through the online marketplace Dr. Cannabis. This partnership aims to expand patient access to medical cannabis in Brazil, where nearly 10,000 import authorizations have been granted since 2014.PR NewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Hires Gabriel Barbosa as Scientific Projects and Regulatory Developing AnalystMedical Marijuana, Inc.'s subsidiary HempMeds\u00ae Brasil has hired Gabriel Barbosa as Scientific Projects and Regulatory Developing Analyst. The hire comes as Brazil's medical cannabis market is projected to grow to $2.4 billion annually within three years if CBD products continue gaining approvals, with regulatory standards for CBD experiencing a positive shift in the country. Barbosa brings expertise in bioprospecting, pharmacology of natural products, and applied microbiology, and aims to help educate Brazilian citizens on cannabinoid medicine and make it more accessible.PR NewswireMedical Marijuana, Inc. and Subsidiaries Kannaway®, HempMeds® Brasil and Phyto Animal Health Announce March 2019 as the Largest Revenue Month in Company HistoryMedical Marijuana, Inc. announced that March 2019 was its largest revenue month in company history, a milestone also achieved by its subsidiaries Kannaway®, HempMeds® Brasil, and Phyto Animal Health. The company celebrated its 10th anniversary and received the U.S. Hemp Authority's Certification Seal for its CBD products during this period. Additional operational milestones included new product launches, sports team sponsorships, and educational events in Brazil.PR NewswireMedical Marijuana, Inc. Subsidiary HempMeds® Brasil Sponsors International Autistic Week in Ribeirao Preto, BrazilMedical Marijuana, Inc. announced that its subsidiary, HempMeds® Brasil, will sponsor TEAbraco 2019 International Autism Week in Ribeirão Preto, Brazil, to educate the public on medical cannabis and CBD products. The company highlighted that CBD is legal and subsidized by the Brazilian government for various indications, including autism, aiming to inform citizens of their eligibility for these benefits.